PTSD Treatment Options: What the Evidence Says and What to Ask Your Prescriber

PTSD is not only a veterans' condition. It can develop after any event in which a person felt their life or physical safety was genuinely threatened — car accidents, assault, medical emergencies, childhood abuse, natural disasters, witnessing violence, sudden loss. The combat trauma association is real, but it represents one corner of a much larger picture.

DSM-5 diagnostic criteria require all four of the following, persisting for more than 30 days and causing meaningful functional impairment:

• Exposure to a traumatic event (directly, as a witness, or learning about a close family member's trauma)
• Intrusion symptoms — flashbacks, nightmares, intrusive memories, intense distress when reminded of the trauma
• Avoidance — of trauma-related thoughts, feelings, people, places, or activities that trigger memories
• Negative cognitions and mood changes — persistent negative beliefs about oneself or the world, estrangement from others, emotional numbing, persistent guilt or shame
• Hyperarousal — hypervigilance, exaggerated startle response, sleep disturbance, irritability or angry outbursts, reckless behavior

Complex PTSD (C-PTSD) is increasingly recognized, particularly in people with childhood trauma or prolonged repeated trauma. C-PTSD shares the classic PTSD clusters but adds identity disturbance, chronic emotional dysregulation, and significant relational difficulties — features that require somewhat different treatment approaches.

Importantly: only about 20% of people exposed to trauma develop PTSD. Risk factors include prior trauma history, lack of social support, trauma severity and duration, peritraumatic dissociation, and female sex. Resilience is the norm — PTSD development is not inevitable, and it does not reflect personal weakness.

Understanding what happens in the brain with PTSD is clinically important — not as an abstraction, but because it explains why certain treatments work and others don't.

The traumatized brain shows three consistent neurological changes:

• Hyperactive amygdala — constantly scanning the environment for threat, responding to cues that resemble the trauma with a full alarm response even when no actual danger exists
• Underactive prefrontal cortex — reduced capacity to contextualize that the danger is past and the threat is not present now; the rational regulation of emotional response is impaired
• Hippocampal changes — the hippocampus, responsible for contextual memory and threat discrimination, shows structural and functional changes in PTSD. This produces fragmented traumatic memories, intrusive re-experiencing, and difficulty distinguishing present-day safety from past threat.

These are documented neurological changes — measurable on imaging, replicated across research populations. PTSD is not a choice, a character flaw, or a sign that someone isn't “tough enough.” It is a biological response to overwhelming experience.

HPA axis dysregulation — the stress-hormone system — also occurs in PTSD, producing altered cortisol patterns that contribute to hyperarousal, sleep disruption, and immune system effects. This biology explains why trauma-focused therapies that directly process the trauma memory tend to be more effective than supportive therapies that manage symptoms without addressing the underlying neural conditioning.

Only two medications currently have FDA approval specifically for PTSD: sertraline (Zoloft) and paroxetine (Paxil) — both SSRIs. They reduce the overall PTSD symptom burden, particularly emotional numbing, depression, anxiety, and some hyperarousal symptoms. They are not curative: approximately 60% of patients respond, with 20–30% achieving full remission. For many people, they are an important component of a broader treatment plan — not the whole plan.

Medications used off-label with good evidence

• Venlafaxine (Effexor XR) — an SNRI with strong clinical trial evidence for PTSD, widely used and considered by many clinicians to be equally first-line despite lacking FDA approval for this indication
• Prazosin — an alpha-1 blocker originally used for blood pressure; specifically targets PTSD-related nightmares and has good evidence for reducing nightmare frequency and severity
• Mirtazapine — helps with sleep, appetite, and depression in PTSD; often used as an adjunct
• Quetiapine — at low doses, useful for sleep disruption and hyperarousal; not first-line but commonly used

Benzodiazepines — not recommended for PTSD

This is a frequently misunderstood point. Despite being commonly prescribed for anxiety, benzodiazepines are not recommended for PTSD. The evidence suggests they may worsen long-term outcomes and interfere with the trauma processing that effective therapy depends on. They prevent the emotional learning that exposure-based treatments require. Multiple clinical guidelines — including VA/DoD — recommend against their use in PTSD.

Emerging: MDMA-assisted therapy

MDMA-assisted psychotherapy is in late-stage clinical trials for PTSD. Phase 3 data has shown substantial remission rates in treatment-resistant PTSD. FDA approval is still pending following the agency's request for additional data, but expanded access protocols are available at some centers. This is one of the most closely watched developments in PTSD treatment.

For most people with PTSD, therapy is where the real work happens. The research on trauma-focused therapies is remarkably strong — and the distinctions between them matter when choosing the right fit.

Trauma-focused CBT approaches

• Prolonged Exposure (PE) — the most extensively researched trauma treatment. Involves repeatedly processing the trauma memory in session (imaginal exposure) and re-engaging with avoided situations (in vivo exposure) until the trauma loses its power. VA/DoD first-line recommendation.
• Cognitive Processing Therapy (CPT) — focuses on identifying and restructuring “stuck points” — distorted beliefs formed by the trauma, such as “It was my fault,” “The world is completely dangerous,” or “I am permanently broken.” VA/DoD first-line recommendation; often preferred for patients who struggle with directly revisiting the trauma memory.
• EMDR (Eye Movement Desensitization and Reprocessing) — uses bilateral stimulation (eye movements, tapping) while briefly activating the trauma memory. The mechanism remains debated, but the clinical evidence is strong, particularly for single-incident trauma. VA/DoD first-line; often works faster than PE or CPT for some presentations.
• Written Exposure Therapy (WET) — a newer, shorter protocol (5 sessions) involving structured writing about the trauma. Phase 2 and 3 trial data shows results comparable to CPT with significantly lower dropout rates. Worth asking about, especially if access to longer protocols is limited.

Non-trauma-focused approaches

• DBT (Dialectical Behavior Therapy) — particularly useful for C-PTSD and significant emotional dysregulation; addresses the skills deficits and instability that can make trauma-focused work difficult
• IFS (Internal Family Systems) — gaining clinical evidence, particularly for complex trauma; a parts-based model that many trauma survivors find intuitively useful
• Somatic therapies — body-based approaches (Somatic Experiencing, sensorimotor psychotherapy) that work with the physiological component of trauma rather than primarily through narrative or cognition; increasingly incorporated into complex trauma treatment

When multiple first-line approaches have not produced adequate response, there are additional options — though the evidence base is thinner and the clinical picture is typically more complex.

• Augmentation with atypical antipsychotics — risperidone, quetiapine, and olanzapine have been studied as add-ons to SSRI treatment in refractory PTSD, with modest but real evidence for hyperarousal and sleep symptoms
• Stellate ganglion block — a nerve block injected into the neck that targets a collection of sympathetic nerve fibers. Pilot and early trial data in refractory PTSD has been promising; it is available at some specialized centers and is gaining attention in military and civilian treatment settings
• Ketamine / esketamine — off-label use with early evidence in PTSD, particularly for co-occurring depression; rapid onset is the primary advantage
• MDMA-assisted psychotherapy — expanded access protocols available at some centers for treatment-resistant cases while the FDA approval process continues; phase 3 data for refractory PTSD has been striking

A critical and often overlooked point: PTSD rarely travels alone. Depression co-occurs in approximately 50% of people with PTSD. Substance use disorder in 30–40%. Chronic pain, traumatic brain injury, and other anxiety disorders are also common. Addressing these comorbidities — not treating PTSD in isolation — often produces significant improvement in PTSD outcomes. A prescriber who is only treating the PTSD without considering the full clinical picture is likely to underperform.

These are the questions worth bringing to your next prescriber appointment — especially if you are newly diagnosed or have not been getting adequate relief from current treatment.

• “Should I try medication, therapy, or both at the same time?” For most people with moderate to severe PTSD, combination treatment produces better outcomes — but the answer depends on availability, severity, and your specific symptom picture.
• “Is there a PTSD specialist or trauma-focused therapist you can refer me to?” PE, CPT, and EMDR are not the same as general talk therapy. Specifically asking for a trauma-focused therapist trained in one of these protocols matters.
• “My main symptoms are [nightmares / hypervigilance / emotional numbing] — which medications target those specifically?” Medication choices can be tailored to dominant symptom clusters. Prazosin for nightmares. Mirtazapine for sleep and appetite. SSRIs/SNRIs for the broader symptom burden. Make the symptom picture explicit.
• “What should I expect in the first few weeks of medication?” SSRIs may produce an initial anxiety bump. Sleep medications may cause next-day sedation. Knowing what is expected versus what warrants a call makes the first weeks more manageable.
• “How long will I need to be on medication?” Guidelines typically suggest 12 months at minimum after achieving response before attempting to taper — but this varies by severity, history, and comorbidities. It is a conversation worth having explicitly from the start.